<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cystic fibrosis: Clinical manifestations of pulmonary disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cystic fibrosis: Clinical manifestations of pulmonary disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cystic fibrosis: Clinical manifestations of pulmonary disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie P Katkin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George B Mallory, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cystic fibrosis (CF) is a multisystem disease affecting the lungs, digestive system, sweat glands, and reproductive tract. Patients with CF have abnormal transport of chloride and sodium across secretory epithelia, resulting in thickened, viscous secretions in the bronchi, biliary tract, pancreas, intestines, and reproductive system [<a href="#rid1">1,2</a>]. Although the disease is systemic, progressive lung disease continues to be the major cause of morbidity and mortality for most patients. The clinical findings described here are characteristic of the disease before the advent of CF transmembrane conductance regulator (CFTR) modulator therapies. These descriptions are still very relevant for patients who do not carry genetic mutations amenable to these medications. The effects of CFTR modulator therapy on disease course has yet to be determined, but it is likely that symptoms and disease progression will be greatly attenuated or slowed [<a href="#rid3">3</a>].</p><p>Clinical manifestations of pulmonary disease are reviewed here. The treatment of CF-associated lung disease is discussed in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/110933.html" rel="external">"Cystic fibrosis: Management of pulmonary exacerbations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease"</a>.)</p><p></p><p>Other aspects of CF care are discussed in these topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14544.html" rel="external">"Cystic fibrosis-related diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5858.html" rel="external">"Cystic fibrosis: Overview of gastrointestinal disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5885.html" rel="external">"Cystic fibrosis: Assessment and management of pancreatic insufficiency"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/99126.html" rel="external">"Cystic fibrosis: Hepatobiliary disease"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PROGRESSION OF PULMONARY DISEASE</span></p><p class="headingAnchor" id="H791324236"><span class="h2">Alterations in respiratory secretions</span><span class="headingEndMark"> — </span>CF is caused by mutations in a single, large gene on chromosome 7 that encodes the CF transmembrane conductance regulator (CFTR) protein [<a href="#rid4">4-6</a>]. CFTR is a regulated chloride channel, which, in turn, may regulate the activity of other chloride and sodium channels at the cell surface. The net result of these changes is an alteration in the rheology of airway secretions, which become thick and difficult to clear [<a href="#rid7">7</a>]. Ultimately, these viscid secretions obstruct the small airways and promote infection, which leads to tissue destruction and eventually to bronchiectasis. (See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a>.)</p><p class="headingAnchor" id="H1531054"><span class="h2">Infection</span><span class="headingEndMark"> — </span>The chronic airway obstruction caused by viscous secretions is soon followed by colonization with pathogenic bacteria, including <em>Haemophilus</em> <em>influenzae</em>, <em>Staphylococcus</em> <em>aureus</em>, <em>Pseudomonas</em> <em>aeruginosa</em>, and <em>Burkholderia</em> <em>cepacia</em> complex species. Methicillin-resistant <em>S</em>. <em>aureus</em> is encountered with increasing frequency in many regions. Other organisms frequently encountered in the CF airways include <em>Stenotrophomonas</em> <em>maltophilia</em>, <em>Achromobacter</em> <em>xylosoxidans</em>, and <em>Klebsiella</em> spp, although the contribution of these pathogens to the development of bronchial disease is not always clear. Chronic bacterial infection within the airways occurs in most patients with CF  (<a class="graphic graphic_table graphicRef55018" href="/d/graphic/55018.html" rel="external">table 1</a>), and the prevalence of each bacterial type varies with the age of the patient  (<a class="graphic graphic_figure graphicRef74073" href="/d/graphic/74073.html" rel="external">figure 1</a>). Even among asymptomatic infants identified by newborn screening, there is evidence of subclinical lung disease within the first few months of life [<a href="#rid8">8-10</a>] (see <a class="local">'Pulmonary function testing'</a> below). Infection with <em>S</em>. <em>aureus</em> and <em>P</em>. <em>aeruginosa</em> are common even in young children with CF. The presence of <em>P</em>. <em>aeruginosa</em> with a mucoid phenotype is particularly suggestive of CF. Nontuberculous mycobacteria and fungal species such as <em>Aspergillus</em> also contribute to clinical disease in many patients. A subset of patients colonized with <em>Aspergillus</em> develop a hypersensitivity reaction known as allergic bronchopulmonary aspergillosis (ABPA), which causes acute or subacute deterioration of pulmonary function. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pathogens'</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Aspergillus species'</a>.)</p><p class="headingAnchor" id="H1531082"><span class="h2">Bronchiectasis</span><span class="headingEndMark"> — </span>Once infection is established, neutrophils are unable to control the bacteria even though there is massive infiltration of these inflammatory cells into the lung tissue. Recruited neutrophils subsequently release elastase, which overwhelms the antiproteases of the lung and contributes to tissue destruction. In addition, large amounts of DNA and cytosol matrix proteins are released by degranulating neutrophils, contributing to the increased viscosity of the airway mucus [<a href="#rid11">11</a>].</p><p>Chronic inflammation causes lung damage, first identified on imaging studies as peribronchial cuffing and mild bronchiectasis. Bronchiectasis is an abnormality of the bronchial tree, associated with impairment of mucociliary clearance in the airway. This begins as mild dilatation of areas of the bronchial walls (fusiform bronchiectasis) and can progress to almost globular expansions of the bronchial tree (saccular bronchiectasis). The walls of bronchiectatic airways are chronically inflamed, and they become weak and easily collapsible, which further limits the effectiveness of mucociliary transport and leads to increased infection. Mild, early bronchiectasis may not be easily visualized on a routine chest radiograph but may be seen on computed tomography (CT) scan. More advanced bronchiectasis may be noted by the radiographic finding of abnormal dilation and distortion of the bronchial tree. Associated findings include atelectasis, emphysema, fibrosis, and hypertrophy of the bronchial vasculature. Clinically, bronchiectasis manifests as daily productive cough in almost all patients (see  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a>). Prospective studies have identified evidence of bronchiectasis by CT in 50 to 75 percent of children with CF by three to five years of age [<a href="#rid9">9,12</a>]. In a study of infants with CF identified by newborn screening, the point prevalence of bronchiectasis on a single CT was approximately 30 percent at 3 months and 12 months of age, 44 percent at two years, and 61 percent at three years. Thirty-two percent had CT evidence of persistent bronchiectasis at three years of age. Important predictors of early bronchiectasis included a history of meconium ileus at birth (odds ratio [OR] 3.17, 95% CI 1.51-6.66), severe genotype (OR 2.54, 95% CI 1.57-4.11), respiratory symptoms at the time of the study (OR 2.57, 95% CI 1.50-4.39), and neutrophil elastase activity in fluid obtained by bronchoalveolar lavage (OR 4.21, 95% CI 1.45-12.21) [<a href="#rid13">13</a>].</p><p>Over time, chronic mucus plugging and chronic infection cause irreparable changes to the airways and damage advances to the stage of irreversible bronchiectasis and progressive respiratory failure [<a href="#rid14">14</a>]. Terminal findings often include severely congested parenchyma with grossly purulent secretions in and around dilated airways  (<a class="graphic graphic_picture graphicRef59374" href="/d/graphic/59374.html" rel="external">picture 1</a>). The airway epithelium is hyperplastic, often with areas of erosion and squamous metaplasia. Plugs of mucoid material and inflammatory cells are often present in the airway lumen  (<a class="graphic graphic_picture graphicRef78974" href="/d/graphic/78974.html" rel="external">picture 2</a>). Submucosal gland hypertrophy and hyperplasia of airway smooth muscle may also be noted [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/6358.html" rel="external">"Bronchiectasis in children: Pathophysiology and causes", section on 'Pathophysiology'</a>.)</p><p>With the advent of new CFTR modulator medications, which modify the function of the abnormal CFTR protein, we anticipate that the progression of lung disease may be significantly delayed in those patients who are eligible for therapy. (See  <a class="medical medical_review" href="/d/html/118899.html" rel="external">"Cystic fibrosis: Treatment with CFTR modulators"</a>.)</p><p class="headingAnchor" id="H735362879"><span class="h2">Variability in progression</span><span class="headingEndMark"> — </span>Progressive lung disease continues to be the major cause of morbidity and mortality for most patients. The rate of progression varies widely, depending in part on genotype (including gene modifiers), as well as environmental factors and the frequency and aggressiveness of treatment of the recurrent infections. Registry data from CF centers in the United States indicate a median predicted survival for an individual born in 2021 of approximately 65 years  (<a class="graphic graphic_figure graphicRef61930" href="/d/graphic/61930.html" rel="external">figure 2</a>) [<a href="#rid16">16</a>]. National registry data from Canada, Italy, and the United Kingdom also note increases in predicted survival over the past decade [<a href="#rid17">17</a>]. Some of these changes have been attributed to earlier diagnosis by means of newborn screening. Females with CF appear to have higher morbidity and mortality than males during the first three decades of life [<a href="#rid18">18</a>]. This sex difference is modest but consistent across many populations, even in the face of improved survival in recent years, and is hypothesized to be due to the proinflammatory effects of estrogens. Interestingly, among people who are diagnosed with CF in adulthood, female patients may actually have a survival advantage compared with their male peers [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/6368.html" rel="external">"Cystic fibrosis: Genetics and pathogenesis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">RESPIRATORY SYMPTOMS AND SIGNS</span><span class="headingEndMark"> — </span>Respiratory symptoms of CF usually begin early in life, although in milder cases, the onset of persistent lung disease may be delayed until the second or third decade [<a href="#rid2">2</a>]. Newborn screening is now performed in many countries, and this identifies most infants before they develop symptoms. Where newborn screening is not performed, pulmonary disease is the primary presenting symptom for approximately 40 percent of children diagnosed with CF. (See  <a class="medical medical_review" href="/d/html/6367.html" rel="external">"Cystic fibrosis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2300632481"><span class="h2">Chronic endobronchial suppurative disease</span><span class="headingEndMark"> — </span>Respiratory manifestations of CF usually start with a recurrent cough that gradually becomes persistent. In young infants, this may manifest as prolonged or recurrent episodes of bronchiolitis with tachypnea and wheezing. Eventually, coughing occurs on a daily basis, becoming productive and often paroxysmal. The productive nature of the cough may be overlooked in young children, who tend to swallow sputum.</p><p>Progressive airway damage and mucus plugging eventually cause chronic obstruction of the airways. As a result, the anteroposterior diameter of the thorax may increase due to progressive air trapping and hyperinflation from airway collapsibility [<a href="#rid21">21,22</a>]. Many older patients have a barrel-shaped chest. Other complications that occur in a minority of patients include spontaneous pneumothorax and hemoptysis, which may be massive [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/6372.html" rel="external">"Cystic fibrosis: Overview of the treatment of lung disease", section on 'Other pulmonary complications'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Airway reactivity</span><span class="headingEndMark"> — </span>Many patients with CF have airway hyperreactivity, which is typically modest. In one study of young children with CF (mean age 16 months), 50 percent had wheezing and 43 percent of children who wheezed were responsive to bronchodilator therapy [<a href="#rid25">25</a>]. Many patients continue to demonstrate bronchial hyperresponsiveness into adolescence and adulthood, with positive correlations between the degree of airway reactivity and overall severity of lung disease. Beta-agonist medications, which are thought to enhance ciliary function and airway patency, are usually part of daily airway clearance for children with CF. Inhaled corticosteroids have been associated with an increased rate of lower respiratory infection, however, so their use is not recommended for CF patients unless they have classic symptoms of asthma (episodic wheezing, often with other atopic symptoms) or allergic bronchopulmonary aspergillosis (ABPA).</p><p>Patients with CF sometimes become less responsive to bronchodilators over time [<a href="#rid14">14</a>]. This phenomenon may occur when progressive airway damage leads to a loss of cartilaginous support, resulting in an increased dependence on muscle tone for maintenance of airway patency. In this setting, the muscle relaxation caused by bronchodilators may cause collapse of such "floppy" airways, leading to increased airflow obstruction.</p><p class="headingAnchor" id="H3091331448"><span class="h2">Allergic bronchopulmonary aspergillosis</span><span class="headingEndMark"> — </span>Although invasive fungal disease is rare in patients with CF, ABPA is increasingly recognized in CF patients. Symptoms are similar to the progressive pulmonary disease that is typical in CF. However, marked exacerbation of wheezing or otherwise unexplained deterioration in lung function despite antibiotic therapy in CF patients should prompt a careful evaluation for this disorder, which causes acute or subacute deterioration of pulmonary function and should be treated. Patients who grow <em>Aspergillus</em> species from respiratory cultures but who do not have evidence of ABPA should be observed closely but usually do not warrant treatment. In most CF centers, patients are screened with annual evaluation of total serum immunoglobulin E (IgE); a sudden increase should prompt further investigation for possible ABPA. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Aspergillus species'</a> and  <a class="medical medical_review" href="/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a>.)</p><p class="headingAnchor" id="H818388937"><span class="h2">Obstructive sleep apnea</span><span class="headingEndMark"> — </span>Children and adults with CF may be at higher risk than typical peers for obstructive sleep apnea (OSA) [<a href="#rid26">26,27</a>]. One study employed polysomnography to evaluate sleep in 40 children with mild and stable CF-associated lung disease [<a href="#rid28">28</a>]. Nearly 70 percent of the CF patients were found to have mild or moderate OSA (defined as an apnea-hypopnea index &gt;2), substantially more than in age-matched controls. OSA was more severe in CF patients younger than six years. The presence of OSA may exacerbate nocturnal hypoxemia and sleep fragmentation, particularly in patients with more severe lung disease [<a href="#rid29">29</a>]. The mechanisms for the association between CF and OSA have not been established, but chronic inflammation and nasopharyngeal obstruction may play a role. Presenting symptoms of OSA are similar to those in individuals without CF. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H3878956256"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Advanced chronic lung disease in CF can be complicated by pulmonary hypertension, which is correlated with severity of lung disease, likely mediated by alveolar hypoxia, acidosis, hypercapnia, and chronic systemic inflammation [<a href="#rid30">30</a>]. As an example, among CF patients listed for lung transplantation, approximately 10 percent had pulmonary hypertension [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Indications for referral to a lung transplant center'</a>.)</p><p>The development of pulmonary hypertension is associated with significantly worse survival. In one study, patients with mild pulmonary hypertension had a hazard ratio (HR) for death of 1.9 (95% CI 1.29-2.85) compared with CF patients without pulmonary hypertension and those with severe pulmonary hypertension had an HR for death of 4.17 (95% CI 1.71-10.16) [<a href="#rid30">30</a>]. In most cases, CF patients with pulmonary hypertension have severe pulmonary compromise (eg, forced expiratory volume in one second [FEV<sub>1</sub>] &lt;40 percent predicted, hypoxemia, or hypercapnia), and the pulmonary hypertension is often identified in the context of evaluation for lung transplantation. If pulmonary hypertension is identified in a CF patient who is not already being considered for transplant, the patient should be offered a referral for transplant evaluation.</p><p>Diagnosis and management of pulmonary hypertension in children and adults is described separately. (See  <a class="medical medical_review" href="/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/109342.html" rel="external">"Pulmonary hypertension in children: Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a> and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">RADIOGRAPHIC FINDINGS</span></p><p class="headingAnchor" id="H7"><span class="h2">Conventional chest radiography</span><span class="headingEndMark"> — </span>Most CF centers monitor patients with chest radiographs at least every two years.</p><p>In patients with mild lung disease, the chest radiograph may appear normal for many years, but, in most patients, at least mild radiographic findings are evident in the first decade of life. The first discernible change is usually hyperinflation, which may initially be reversible with treatment for acute exacerbations of infection. As the disease progresses, hyperinflation becomes persistent and the bronchovascular markings become more prominent. For unclear reasons, abnormalities tend to appear in the upper lobes first, progressing to the lower lobes with advancing disease.</p><p>With time, the bronchovascular markings progress to a pattern of bronchiectasis and cyst formation. Peribronchial cuffing and "tram tracks" (parallel lines caused by thickened bronchial walls in longitudinal section) appear, followed by the rounded shadows of saccular bronchiectasis  (<a class="graphic graphic_diagnosticimage graphicRef56034" href="/d/graphic/56034.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/d/html/6360.html" rel="external">"Bronchiectasis in children: Clinical manifestations and evaluation"</a>.)</p><p>Increasing hyperinflation leads to progressive flattening of the diaphragms, a prominent retrosternal space, and kyphosis in late stages of disease  (<a class="graphic graphic_diagnosticimage graphicRef71098 graphicRef55878" href="/d/graphic/71098.html" rel="external">image 2A-B</a>). Thin-walled cysts (most common in the upper lobes) may appear to extend to the lung surface, and pneumothorax is observed with increasing frequency in older patients. In advanced stages of disease, the chest radiograph may demonstrate little or no correlation with acute clinical changes.</p><p>With good clinical care and careful attention to daily airway clearance, progression of lung disease may be delayed such that the classic radiographic signs of CF do not develop for many years.</p><p class="headingAnchor" id="H8"><span class="h2">Computed tomography</span><span class="headingEndMark"> — </span>CT of the chest may be helpful in defining the extent of bronchiectasis in some patients [<a href="#rid31">31</a>]. It is typically performed in selected patients when a detailed understanding of the extent of lung disease is needed to make a clinical decision. As an example, chest CT is of particular interest in patients who have focal areas of advanced disease, which may sometimes be amenable to surgical resection, although this is rarely undertaken. CT surveillance may also be useful to monitor the presence and/or progression of disease caused by atypical mycobacteria.</p><p>High-resolution CT (HRCT) scanning is the most useful technique and may demonstrate evidence of unsuspected air trapping and inhomogeneities of lung inflation even in very young asymptomatic children; it is thus a sensitive indicator of early disease in children too young to perform pulmonary function testing [<a href="#rid32">32</a>]. As the lung disease progresses, HRCT findings typically include mucus plugging, centrilobular nodules, peribronchial thickening, air-trapping, and bronchiectasis (characterized by increased diameter of the airway compared with the adjacent artery and/or bronchi)  (<a class="graphic graphic_diagnosticimage graphicRef53471" href="/d/graphic/53471.html" rel="external">image 3</a>) [<a href="#rid33">33</a>] (see  <a class="medical medical_review" href="/d/html/1444.html" rel="external">"Clinical manifestations and diagnosis of bronchiectasis in adults", section on 'Computed tomography'</a>). Increased pulmonary artery diameter suggests pulmonary hypertension. More studies will be needed to determine the role of serial CT scanning in the evaluation and care of CF patients, balancing the risk of repeated exposure to radiation with the potential benefits of earlier identification of bronchiectasis [<a href="#rid34">34</a>].</p><p>The degree of bronchiectasis noted on CT is associated with infection with mucoid strains of <em>P</em>. <em>aeruginosa</em> [<a href="#rid35">35</a>]. However, the degree of bronchiectasis is only weakly correlated with measures of pulmonary function and is not well correlated with exercise performance [<a href="#rid35">35,36</a>]. Serial HRCT scans often display progressively severe disease despite apparently stable pulmonary function [<a href="#rid37">37-39</a>]. Thus, changes in pulmonary function may be more subtle than or lag behind the CT abnormalities.</p><p class="headingAnchor" id="H3320675625"><span class="h2">Magnetic resonance imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) of the chest has not been well validated as an approach to tracking CF pulmonary disease. The few existing studies indicate that MRI may overestimate the degree of bronchiectasis in patients with relatively mild disease and underestimate bronchiectasis in patients with more severe disease. Improving technology allows better imaging of the lung using MRI, producing better concordance between CT and MRI images of the lung. Newer MRI techniques can provide improved functional imaging of the lung (eg, superior evaluation of regional perfusion), but the imaging detail is still somewhat inferior to CT for imaging structural disease [<a href="#rid40">40,41</a>]. Preliminary data from a study that used both techniques suggest that bronchiectasis scores on both MRI and CT are correlated with pulmonary function, but MRI still tended to overestimate bronchiectasis compared with CT [<a href="#rid42">42</a>]. In this study, MRI bronchiectasis scores were also correlated with pulmonary exacerbations, <em>P</em>. <em>aeruginosa</em> infection, and patient-reported respiratory symptoms. As clinicians increasingly seek to identify structural changes in the lungs of CF patients, lifetime exposure to radiation is becoming a serious concern. MRI may become a useful, safer alternative to serial CT scanning but is not yet appropriate for widespread use.</p><p class="headingAnchor" id="H9"><span class="h2">Contrast bronchography</span><span class="headingEndMark"> — </span>Since the advent of CT scanning, there is no clinical indication for contrast bronchography. When used in the past, they often provided evidence of saccular bronchiectasis in patients with advanced CF  (<a class="graphic graphic_diagnosticimage graphicRef61165" href="/d/graphic/61165.html" rel="external">image 4</a>).</p><p class="headingAnchor" id="H10"><span class="h1">PULMONARY FUNCTION TESTING</span><span class="headingEndMark"> — </span>Pulmonary function testing is used in serial fashion to assess disease severity and progression. Reliable spirometry can be performed by many children aged three to six years using modified acceptability criteria [<a href="#rid43">43,44</a>], and the majority of children ages six and older can perform reliable spirometry and plethysmographic lung volumes. Once the patient is old enough for reliable testing, spirometry is performed at regular intervals, typically approximately every three months. (See  <a class="medical medical_review" href="/d/html/5735.html" rel="external">"Overview of pulmonary function testing in children"</a>.)</p><p>In infants with CF, subtle changes in lung structure and function may be identifiable from a very early age, even before clinical signs of disease are apparent [<a href="#rid45">45-47</a>]. Pulmonary function tests (PFTs) in infants are performed using a technique of forced expiration and are well validated. In infants with CF, the tests typically are normal at the time of diagnosis by newborn screening but may deteriorate by six months of age [<a href="#rid48">48</a>]. The decline in infant pulmonary function is associated with signs of pulmonary inflammation and infection [<a href="#rid10">10</a>]. Infant lung function tests have been shown to correlate with results of standard PFTs performed six years later [<a href="#rid49">49</a>]. While infant PFTs are sometimes used for routine clinical management in centers where they are available, they are more often used for research purposes.</p><p>Over time, the majority of CF patients develop an obstructive pattern on PFT. The most sensitive measures of early airway obstruction are increases in the ratio of residual volume to total lung capacity (RV/TLC) and decreases in the forced expiratory flow at 25 to 75 percent of lung volume (FEF<sub>25-75</sub>). As the disease progresses, spirometry reveals a decline in the forced expiratory volume in one second (FEV<sub>1</sub>) and the ratio of FEV<sub>1</sub> to forced vital capacity (FEV<sub>1</sub>/FVC) [<a href="#rid21">21</a>]. Lung volumes demonstrate increases in TLC and RV as hyperinflation progresses. (See  <a class="medical medical_review" href="/d/html/5735.html" rel="external">"Overview of pulmonary function testing in children"</a> and  <a class="medical medical_review" href="/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults"</a>.)</p><p>A technique of multiple-breath inert gas washout has been employed to detect early lung disease in infants and young children with CF. This technique appears to have greater sensitivity to detect early airway obstruction as compared with spirometry and may have future research applications in evaluating new therapies [<a href="#rid50">50,51</a>].</p><p>CF patients demonstrate greater within-patient variability in pulmonary function than do normal subjects, even with extensive practice in performance of the maneuvers. These variations reflect fluctuations in the degree of airway inflammation, so PFTs are reliable indicators of acute changes in respiratory function. As an example, the FEV<sub>1</sub> and FVC may drop 10 to 15 percent with acute exacerbations and return to "baseline" values after several weeks of treatment. These fluctuations are often used as indicators for the adequacy of treatment during acute flares of bronchitis.</p><p>Despite intensive therapy, pulmonary function gradually decreases as patients get older, although the pattern of change is unpredictable and varies greatly among individuals. The patterns that may be seen include [<a href="#rid21">21</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Linear decreases in FVC and FEV<sub>1</sub></p><p class="bulletIndent1"><span class="glyph">●</span>Near-normal pulmonary function for many years, followed by a rapid decline</p><p class="bulletIndent1"><span class="glyph">●</span>Stepwise decreases in measurements of pulmonary function, separated by years of stability at a new level of function</p><p></p><p>The FEV<sub>1</sub> is correlated with survival in CF patients. In a large observational study, predictors of the rate of decline in FEV<sub>1</sub> included poor nutritional status, <em>P</em>. <em>aeruginosa</em> infection, persistent crackles on examination, and frequency of pulmonary exacerbations [<a href="#rid52">52</a>]. Patients with mild pulmonary function abnormalities (high FEV<sub>1</sub>) sometimes experience rapid declines, suggesting that even patients with apparently high lung function as well as young children should be followed regularly with spirometry. Referral to a lung transplant center has been suggested for patients with FEV<sub>1</sub> &lt;50 percent predicted and rapidly declining, or an FEV<sub>1</sub> persistently &lt;30 percent predicted [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Lung transplant evaluation'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">MONITORING GAS EXCHANGE</span><span class="headingEndMark"> — </span>Oxygen saturation should be measured using pulse oximetry when a patient presents with an acute pulmonary exacerbation. It should also be monitored routinely in patients with moderate to severe pulmonary disease to assess the need for supplemental oxygen [<a href="#rid54">54</a>]. For those with severe pulmonary disease, the possible presence of hypercapnia should be evaluated by measuring end-tidal carbon dioxide (CO<sub>2</sub>) or via arterial blood gas analysis. If hypercapnia is present, the patient may benefit from noninvasive ventilation during sleep. A six-minute walk test can be used to assess oxygenation during physical activity and is often used to monitor functional status after transplant. (See  <a class="medical medical_review" href="/d/html/129117.html" rel="external">"Cystic fibrosis: Management of advanced lung disease", section on 'Supplemental oxygen'</a>.)</p><p>As bronchiectasis and airway obstruction become more pronounced, ventilation-perfusion mismatch leads to hypoxemia. This may initially occur only during sleep or exercise, but patients with advanced disease often require continuous oxygen supplementation. Hypercapnia occurs relatively late in the course of CF lung disease. (See  <a class="medical medical_review" href="/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a>.)</p><p>Regions of chronic alveolar hypoxemia may eventually lead to muscular hypertrophy of the pulmonary vasculature with pulmonary hypertension, right ventricular hypertrophy, and, eventually, cor pulmonale with right heart failure. (See <a class="local">'Pulmonary hypertension'</a> above.)</p><p>Polycythemia typically occurs in patients with congenital heart disease as a physiologic compensation for chronic hypoxemia. By contrast, polycythemia is a rare finding in CF [<a href="#rid55">55,56</a>]. Several factors may prevent the polycythemic response in patients with CF, including the anemia of chronic disease and iron deficiency. In addition, blood volume tends to increase as the disease progresses, so absolute increases in red cell mass may not be reflected in the hematocrit.</p><p class="headingAnchor" id="H3704653907"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109226.html" rel="external">"Society guideline links: Cystic fibrosis"</a>.)</p><p class="headingAnchor" id="H11005224"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16906.html" rel="external">"Patient education: Cystic fibrosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16847652"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cystic fibrosis (CF) is characterized by chronic airway obstruction caused by viscous respiratory secretions. This predisposes to chronic pulmonary infection with pathogenic bacteria, including <em>Haemophilus</em> <em>influenzae</em>, <em>Staphylococcus</em> <em>aureus</em>, <em>Pseudomonas</em> <em>aeruginosa</em>, and <em>Burkholderia</em> <em>cepacia</em> complex species  (<a class="graphic graphic_table graphicRef55018" href="/d/graphic/55018.html" rel="external">table 1</a>); the prevalence of each bacterial type varies with the age of the patient  (<a class="graphic graphic_figure graphicRef74073" href="/d/graphic/74073.html" rel="external">figure 1</a>). (See <a class="local">'Infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic inflammation causes lung damage that ultimately advances to the stage of irreversible bronchiectasis (abnormal dilation and distortion of the bronchial tree) and progressive respiratory failure. Terminal findings often include severely congested parenchyma, with grossly purulent secretions in and around dilated airways  (<a class="graphic graphic_picture graphicRef59374" href="/d/graphic/59374.html" rel="external">picture 1</a>). (See <a class="local">'Bronchiectasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Respiratory manifestations of CF usually start with a recurrent cough that gradually becomes persistent. In young infants, this may manifest as prolonged or recurrent episodes of bronchiolitis with tachypnea and wheezing. Eventually, coughing occurs on a daily basis, becoming productive and often paroxysmal. (See <a class="local">'Respiratory symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Airway hyperreactivity is a common finding in CF patients, manifested by wheezing that is initially responsive to bronchodilator therapy. However, as the disease progresses, the airway tends to become floppier and patients may become unresponsive to bronchodilator administration. (See <a class="local">'Airway reactivity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging findings</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Conventional chest radiographs are used to monitor disease progression in patients with CF lung disease. The chest radiograph may appear normal for the first few years of life or longer in patients with mild disease. The first discernible change is usually hyperinflation. Later, bronchovascular markings become more prominent. In advanced disease, the chest radiograph reveals peribronchial cuffing and "tram tracks," followed by the rounded shadows of saccular bronchiectasis  (<a class="graphic graphic_diagnosticimage graphicRef56034" href="/d/graphic/56034.html" rel="external">image 1</a>). (See <a class="local">'Conventional chest radiography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-resolution CT (HRCT) is performed in selected patients when a sensitive measure of CF lung disease is required for clinical purposes. Serial HRCT scans may detect progressive disease before changes are noted in pulmonary function tests (PFTs) or clinical symptoms. The clinical utility of HRCT in making management decisions has not been established. (See <a class="local">'Computed tomography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PFTs</strong> – CF is characterized by progressive obstructive abnormalities on PFT testing. PFT findings vary with acute changes in respiratory function. In addition, patients exhibit an overall declining trend in pulmonary function as their disease progresses, but the decline may not be linear. Decline in FEV<sub>1</sub> is associated with diminished survival and is an important indicator for determining referral to a lung transplant center. (See <a class="local">'Pulmonary function testing'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992.</a></li><li><a class="nounderline abstract_t">Ratjen F, Döring G. Cystic fibrosis. Lancet 2003; 361:681.</a></li><li><a class="nounderline abstract_t">De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr 2020; 109:893.</a></li><li><a class="nounderline abstract_t">Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.</a></li><li><a class="nounderline abstract_t">Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256:774.</a></li><li><a class="nounderline abstract_t">Drumm ML, Collins FS. Molecular biology of cystic fibrosis. Mol Genet Med 1993; 3:33.</a></li><li><a class="nounderline abstract_t">Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999; 103:309.</a></li><li><a class="nounderline abstract_t">Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180:146.</a></li><li><a class="nounderline abstract_t">Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009; 155:623.</a></li><li><a class="nounderline abstract_t">Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184:75.</a></li><li><a class="nounderline abstract_t">Margaroli C, Garratt LW, Horati H, et al. Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis. Am J Respir Crit Care Med 2019; 199:873.</a></li><li><a class="nounderline abstract_t">Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67:509.</a></li><li><a class="nounderline abstract_t">Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013; 368:1963.</a></li><li><a class="nounderline abstract_t">Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918.</a></li><li><a class="nounderline abstract_t">Hays SR, Ferrando RE, Carter R, et al. Structural changes to airway smooth muscle in cystic fibrosis. Thorax 2005; 60:226.</a></li><li class="breakAll">Cystic Fibrosis Foundation. 2021 Patient Registry: Annual Data Report. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf (Accessed on November 10, 2022).</li><li><a class="nounderline abstract_t">Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med 2018; 24:574.</a></li><li><a class="nounderline abstract_t">Sweezey NB, Ratjen F. The cystic fibrosis gender gap: potential roles of estrogen. Pediatr Pulmonol 2014; 49:309.</a></li><li><a class="nounderline abstract_t">McIntyre K. Gender and survival in cystic fibrosis. Curr Opin Pulm Med 2013; 19:692.</a></li><li class="breakAll">Cystic Fibrosis Canada. 2020 Annual Data Report: The Canadian Cystic Fibrosis Registry. 2022. Available at: https://www.cysticfibrosis.ca/registry/2020AnnualDataReport.pdf (Accessed on February 01, 2023).</li><li class="breakAll">Davis PB. Pathophysiology of the lung disease in cystic fibrosis. In: Cystic Fibrosis (Lung Biology in Health and Disease), Davis PB (Ed), Marcel Dekker, 1993. p.193.</li><li><a class="nounderline abstract_t">Laurin LP, Jobin V, Bellemare F. Sternum length and rib cage dimensions compared with bodily proportions in adults with cystic fibrosis. Can Respir J 2012; 19:196.</a></li><li><a class="nounderline abstract_t">Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.</a></li><li><a class="nounderline abstract_t">Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest 2005; 128:729.</a></li><li><a class="nounderline abstract_t">Hiatt P, Eigen H, Yu P, Tepper RS. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 1988; 137:119.</a></li><li><a class="nounderline abstract_t">Reiter J, Gileles-Hillel A, Cohen-Cymberknoh M, et al. Sleep disorders in cystic fibrosis: A systematic review and meta-analysis. Sleep Med Rev 2020; 51:101279.</a></li><li><a class="nounderline abstract_t">Barbosa RRB, Liberato FMG, de Freitas Coelho P, et al. Sleep-disordered breathing and markers of morbidity in children and adolescents with cystic fibrosis. Pediatr Pulmonol 2020; 55:1974.</a></li><li><a class="nounderline abstract_t">Spicuzza L, Sciuto C, Leonardi S, La Rosa M. Early occurrence of obstructive sleep apnea in infants and children with cystic fibrosis. Arch Pediatr Adolesc Med 2012; 166:1165.</a></li><li><a class="nounderline abstract_t">Shakkottai A, Nasr SZ, Hassan F, et al. Sleep-disordered breathing in cystic fibrosis. Sleep Med 2020; 74:57.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Tobias JD, Mansour HM, et al. Pulmonary hypertension in cystic fibrosis with advanced lung disease. Am J Respir Crit Care Med 2014; 190:898.</a></li><li><a class="nounderline abstract_t">de Jong PA, Ottink MD, Robben SG, et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004; 231:434.</a></li><li><a class="nounderline abstract_t">Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005; 172:1246.</a></li><li><a class="nounderline abstract_t">Shah RM, Sexauer W, Ostrum BJ, et al. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997; 169:375.</a></li><li><a class="nounderline abstract_t">Kuo W, Ciet P, Tiddens HA, et al. Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective. Am J Respir Crit Care Med 2014; 189:1328.</a></li><li><a class="nounderline abstract_t">Farrell PM, Collins J, Broderick LS, et al. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology 2009; 252:534.</a></li><li><a class="nounderline abstract_t">Edwards EA, Narang I, Li A, et al. HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis. Eur Respir J 2004; 24:538.</a></li><li><a class="nounderline abstract_t">de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23:93.</a></li><li><a class="nounderline abstract_t">Cademartiri F, Luccichenti G, Palumbo AA, et al. Predictive value of chest CT in patients with cystic fibrosis: a single-center 10-year experience. AJR Am J Roentgenol 2008; 190:1475.</a></li><li><a class="nounderline abstract_t">de Jong PA, Tiddens HA. Cystic fibrosis specific computed tomography scoring. Proc Am Thorac Soc 2007; 4:338.</a></li><li><a class="nounderline abstract_t">Puderbach M, Eichinger M, Haeselbarth J, et al. Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest x-ray. Invest Radiol 2007; 42:715.</a></li><li><a class="nounderline abstract_t">Eichinger M, Heussel CP, Kauczor HU, et al. Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. J Magn Reson Imaging 2010; 32:1370.</a></li><li><a class="nounderline abstract_t">Tepper LA, Ciet P, Caudri D, et al. Validating chest MRI to detect and monitor cystic fibrosis lung disease in a pediatric cohort. Pediatr Pulmonol 2016; 51:34.</a></li><li><a class="nounderline abstract_t">Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007; 175:1304.</a></li><li><a class="nounderline abstract_t">Rosenfeld M, Allen J, Arets BH, et al. An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age. Ann Am Thorac Soc 2013; 10:S1.</a></li><li><a class="nounderline abstract_t">Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004; 144:154.</a></li><li><a class="nounderline abstract_t">Castile RG, Iram D, McCoy KS. Gas trapping in normal infants and in infants with cystic fibrosis. Pediatr Pulmonol 2004; 37:461.</a></li><li><a class="nounderline abstract_t">Belessis Y, Dixon B, Hawkins G, et al. Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index. Am J Respir Crit Care Med 2012; 185:862.</a></li><li><a class="nounderline abstract_t">Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238.</a></li><li><a class="nounderline abstract_t">Harrison AN, Regelmann WE, Zirbes JM, Milla CE. Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44:330.</a></li><li><a class="nounderline abstract_t">Aurora P, Gustafsson P, Bush A, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004; 59:1068.</a></li><li><a class="nounderline abstract_t">Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008; 63:129.</a></li><li><a class="nounderline abstract_t">Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151:134.</a></li><li><a class="nounderline abstract_t">Ramos KJ, Smith PJ, McKone EF, et al. Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines. J Cyst Fibros 2019; 18:321.</a></li><li><a class="nounderline abstract_t">Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125:1S.</a></li><li><a class="nounderline abstract_t">O'connor TM, McGrath DS, Short C, et al. Subclinical anaemia of chronic disease in adult patients with cystic fibrosis. J Cyst Fibros 2002; 1:31.</a></li><li><a class="nounderline abstract_t">Ater JL, Herbst JJ, Landaw SA, O'Brien RT. Relative anemia and iron deficiency in cystic fibrosis. Pediatrics 1983; 71:810.</a></li></ol></div><div id="topicVersionRevision">Topic 6369 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888700" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606185" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31899933" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cystic fibrosis in the year 2020: A disease with a new face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2772657" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Identification of the cystic fibrosis gene: chromosome walking and jumping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1375392" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cystic fibrosis: molecular biology and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7693108" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular biology of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9927490" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The genesis of cystic fibrosis lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372250" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616787" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493738" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Infection, inflammation, and lung function decline in infants with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281324" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22201161" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23692169" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for bronchiectasis in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555458" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pathophysiology and management of pulmonary infections in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741440" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Structural changes to airway smooth muscle in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741440" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Structural changes to airway smooth muscle in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281026" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cystic fibrosis survival: the changing epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339235" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The cystic fibrosis gender gap: potential roles of estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048080" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gender and survival in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048080" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gender and survival in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24048080" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gender and survival in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22679612" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Sternum length and rib cage dimensions compared with bodily proportions in adults with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100160" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pneumothorax in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100161" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Massive hemoptysis in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3337451" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bronchodilator responsiveness in infants and young children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145647" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sleep disorders in cystic fibrosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364318" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sleep-disordered breathing and markers of morbidity in children and adolescents with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early occurrence of obstructive sleep apnea in infants and children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32841845" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sleep-disordered breathing in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary hypertension in cystic fibrosis with advanced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064392" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100011" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Computed tomography in the evaluation of cystic fibrosis lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242738" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24697683" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19703887" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459130" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738238" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492894" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictive value of chest CT in patients with cystic fibrosis: a single-center 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17652497" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cystic fibrosis specific computed tomography scoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest x-ray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21105141" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436668" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Validating chest MRI to detect and monitor cystic fibrosis lung disease in a pediatric cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545458" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23607855" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760252" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Structural airway abnormalities in infants and young children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095331" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gas trapping in normal infants and in infants with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22323305" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787217" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lung function in infants with cystic fibrosis diagnosed by newborn screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19274621" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Longitudinal assessment of lung function from infancy to childhood in patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563707" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675316" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643762" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30926322" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14734689" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cystic fibrosis adult care: consensus conference report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15463807" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Subclinical anaemia of chronic disease in adult patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6835767" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Relative anemia and iron deficiency in cystic fibrosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
